Mitochondrial NRG™ | Stuðningur við efnaskipti hvatbera og frumuorkuframleiðslu | Heilsubarinn

Mitochondrial NRG™ | Stuðningur við efnaskipti hvatbera og frumuorkuframleiðslu

10.550 kr

Mitochondrial NRG™ | Stuðningur við efnaskipti hvatbera og frumuorkuframleiðslu

10.550 kr
Thumbnail for Mitochondrial NRG™ | Stuðningur við efnaskipti hvatbera og frumuorkuframleiðslu | Heilsubarinn Thumbnail for Mitochondrial NRG™ | Stuðningur við efnaskipti hvatbera og frumuorkuframleiðslu | Heilsubarinn
Mitochondrial NRG™ | Stuðningur við efnaskipti hvatbera og frumuorkuframleiðslu | Heilsubarinn
Mitochondrial NRG™ | Stuðningur við efnaskipti hvatbera og frumuorkuframleiðslu | Heilsubarinn

Mitochondrial NRG™ | Stuðningur við efnaskipti...

10.550 kr

• Alhliða blanda fyrir hvatbera og frumuorku
• Stuðlar að eðlilegri ATP orkuframleiðslu
• Inniheldur CoQ10, R-lípósýru, L-karnitín, D-ríbósa og B-vítamín
• Styður andoxunarvirkni og heilsu heila
• Dregur úr þreytu og eykur lífsþrótt

Frí sending yfir 15 þúsund krónur. Pantanir eru afgreiddar samdægurs ef pantað er fyrir kl. 13, annars daginn eftir (virka daga). Ekki er afgreitt um helgar. Þær eru afhentar með Dropp, á þann stað sem þú velur.

Örugg greiðslulausn með Saltpay eða Netgíró.

Auðveld skil með Dropp.
Nánari Lýsing

Mitochondrial NRG™ er samvirk blanda af næringarefnum og jurtaefnum sem ætlað er að styðja við starfsemi hvatbera, sem framleiða meira en 90% af orku frumna (ATP).

Skilvirkir hvatberar geta stutt við eðlilegt orkustig, almenna vellíðan og heilbrigða líkamsamsetningu.

Formúlan veitir hvatberunum lykilnæringarefni sem eru nauðsynleg fyrir orkuferla líkamans. Þetta felur í sér Coenzyme Q10, R-lípósýru, L-karnitín (sem aðstoðar við að flytja fitu inn í hvatberana til orkuvinnslu) og D-ríbósa.

Einnig inniheldur blandan sértækar sýrur (eplasýru og bergsýru) sem eru þátttakendur í Krebs-ferlinum, sem er ein helsta orkuvinnsluleiðin í hvatberunum.

Virk B-vítamín styðja við mörg skref í orkuframleiðsluferlinu.

Resveratrol og curcumín eru jurtir sem styðja við heilsu hvatbera innan frumunnar og andoxunarvirkni, sem getur hjálpað til við að vinna gegn uppsöfnun frjálsra radíkala.

Fyrir Hverja:
Mitochondrial NRG™ hentar öllum sem vilja styðja við eðlilega frumuorkuframleiðslu, heilaheilsu og stuðla að viðhaldi hvatbera með aldrinum.

ÍTARLEGRI UPPLÝSINGAR

Taktu 4 hylki á dag með máltíðum eða samkvæmt ráðleggingum heilbrigðisstarfsmanns. (Mælt er með að skipta skammtinum upp yfir daginn.)

1. Rose J, Brian C, Woods J, et al. Mitochondrial dysfunction in glial cells: implications for neuronal homeostasis and survival. Toxicology. 2017;391:109‑115. doi:10.1016/j.tox.2017.06.011.

2. Tilokani L, Nagashima S, Paupe V, Prudent J. Mitochondrial dynamics: overview of molecular mechanisms. Essays Biochem. 2018;62(3):341‑360. doi:10.1042/EBC20170104.

3. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta‑analysis. Mol Psychiatry. 2012;17(3):290‑314. doi:10.1038/mp.2010.136.

4. Briston T, Hicks AR. Mitochondrial dysfunction and neurodegenerative proteinopathies: mechanisms and prospects for therapeutic intervention. Biochem Soc Trans. 2018;46(4):829‑842. doi:10.1042/BST20180025.

5. van Horssen J, van Schaik P, Witte M. Inflammation and mitochondrial dysfunction: a vicious circle in neurodegenerative disorders? Neurosci Lett. 2019;710:132931. doi:10.1016/j.neulet.2017.06.050.

6. Elfawy HA, Das B. Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: etiologies and therapeutic strategies. Life Sci. 2019;218:165‑184. doi:10.1016/j.lfs.2018.12.029.

7. Subramaniam SR, Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson’s disease. Prog Neurobiol. 2013;106‑107:17‑32. doi:10.1016/j.pneurobio.2013.04.004.

8. Park JS, Davis RL, Sue CM. Mitochondrial dysfunction in Parkinson’s disease: new mechanistic insights and therapeutic perspectives. Curr Neurol Neurosci Rep. 2018;18(5):21. doi:10.1007/s11910‑018‑0829‑3.

9. Bansal Y, Kuhad A. Mitochondrial dysfunction in depression. Curr Neuropharmacol. 2016;14(6):610‑618. doi:10.2174/1570159x14666160229114755.

10. Chistiakov DA, Shkurat TP, Melnichenko AA, Grechko AV, Orekhov AN. The role of mitochondrial dysfunction in cardiovascular disease: a brief review. Ann Med. 2018;50(2):121‑127. doi:10.1080/07853890.2017.1417631

11. Sánchez‑Domínguez B, Bullón P, Román‑Malo L, et al. Oxidative stress, mitochondrial dysfunction and, inflammation common events in skin of patients with fibromyalgia. Mitochondrion. 2015;21:69‑75. doi:10.1016/j.mito.2015.01.010.

12. Morris G, Maes M. Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno‑inflammatory, oxidative and nitrosative stress pathways. Metab Brain Dis. 2014;29(1):19‑36. doi:10.1007/s11011‑013‑9435‑x.

13. Zhang J, Bao Y, Zhou X, Zheng L. Polycystic ovary syndrome and mitochondrial dysfunction. Reprod Biol Endocrinol. 2019;17(1):67. doi:10.1186/s12958‑019‑0509‑4.

14. Bhatti JS, Bhatti GK, Reddy PH. Mitochondrial dysfunction and oxidative stress in metabolic disorders ‑ A step towards mitochondria based therapeutic strategies. Biochim Biophys Acta Mol Basis Dis. 2017;1863(5):1066‑1077. doi:10.1016/j. bbadis.2016.11.010.

15. Wei PZ, Szeto CC. Mitochondrial dysfunction in diabetic kidney disease. Clin Chim Acta. 2019;496:108‑116. doi:10.1016/j.cca.2019.07.005.

16. Forbes JM, Thorburn DR. Mitochondrial dysfunction in diabetic kidney disease. Nat Rev Nephrol. 2018;14(5):291‑312. doi:10.1038/nrneph.2018.9.

17. Hargreaves I, Heaton RA, Mantle D. Disorders of human coenzyme Q10 metabolism: an overview. Int J Mol Sci. 2020;21(18):6695. doi:10.3390/ijms21186695.

18. Gutierrez‑Mariscal FM, Arenas‑de Larriva AP, Limia‑Perez L, Romero‑Cabrera JL, Yubero‑Serrano EM, López‑Miranda J. Coenzyme Q10 supplementation for the reduction of oxidative stress: clinical implications in the treatment of chronic diseases. Int J Mol Sci. 2020;21(21):7870. doi:10.3390/ijms21217870.

19. Acosta MJ, Vazquez Fonseca L, Desbats MA, et al. Coenzyme Q biosynthesis in health and disease. Biochim Biophys Acta. 2016;1857(8):1079‑1085. doi:10.1016/j.bbabio.2016.03.036.

20. Gutierrez‑Mariscal FM, Yubero‑Serrano EM, Villalba JM, Lopez‑Miranda J. Coenzyme Q10: from bench to clinic in aging diseases, a translational review. Crit Rev Food Sci Nutr. 2019;59(14):2240‑2257. doi:10.1080/10408398.2018.1442316.

21. Wesselink E, Koekkoek WAC, Grefte S, Witkamp RF, van Zanten ARH. Feeding mitochondria: potential role of nutritional components to improve critical illness convalescence. Clin Nutr. 2019;38(3):982‑995. doi:10.1016/j.clnu.2018.08.032.

22. Mehrabani S, Askari G, Miraghajani M, Tavakoly R, Arab A. Effect of coenzyme Q10 supplementation on fatigue: a systematic review of interventional studies. Complement Ther Med. 2019;43:181‑187. doi:10.1016/j.ctim.2019.01.022.

23. Jafari M, Mousavi SM, Asgharzadeh A, Yazdani N. Coenzyme Q10 in the treatment of heart failure: a systematic review of systematic reviews. Indian Heart J. 2018;70(suppl 1):S111‑S117. doi:10.1016/j.ihj.2018.01.031.

24. Lowry E, Marley J, McVeigh JG, McSorley E, Allsopp P, Kerr D. Dietary interventions in the management of fibromyalgia: a systematic review and best‑evidence synthesis. Nutrients. 2020;12(9):2664. doi:10.3390/nu12092664.

25. Sawaddiruk P, Apaijai N, Paiboonworachat S, et al. Coenzyme Q10 supplementation alleviates pain in pregabalin‑treated fibromyalgia patients via reducing brain activity and mitochondrial dysfunction. Free Radic Res. 2019;53(8):901‑909. doi:10.1080/10715762.2019.1645955.

26. Sanoobar M, Eghtesadi S, Azimi A, et al. Coenzyme Q10 supplementation ameliorates inflammatory markers in patients with multiple sclerosis: a double blind, placebo, controlled randomized clinical trial. Nutr Neurosci. 2015;18(4):169‑176. doi:10.1179/1476830513Y.0000000106.

27. Rochette L, Ghibu S, Muresan A, Vergely C. Alpha‑lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Can J Physiol Pharmacol. 2015;93(12):1021‑1027. doi:10.1139/cjpp‑2014‑0353.

28. Salehi B, Berkay Yılmaz Y, Antika G, et al. Insights on the use of α‑lipoic acid for therapeutic purposes. Biomolecules. 2019;9(8):356. doi:10.3390/biom9080356.

29. Solmonson A, DeBerardinis RJ. Lipoic acid metabolism and mitochondrial redox regulation. J Biol Chem. 2018;293(20):7522‑7530. doi:10.1074/jbc.TM117.000259.

30. Gosselin LE, Chrapowitzky L, Rideout TC. Metabolic effects of α‑lipoic acid supplementation in pre‑diabetics: a randomized, placebo‑controlled pilot study. Food Funct. 2019;10(9):5732‑5738. doi:10.1039/c9fo00390h.

31. Kucukgoncu S, Zhou E, Lucas KB, Tek C. Alpha‑lipoic acid (ALA) as a supplementation for weight loss: results from a meta‑analysis of randomized controlled trials. Obes Rev. 2017;18(5):594‑601. doi:10.1111/obr.12528.

32. Rahimlou M, Asadi M, Banaei Jahromi N, Mansoori A. Alpha‑lipoic acid (ALA) supplementation effect on glycemic and inflammatory biomarkers: a systematic review and meta‑analysis. Clin Nutr ESPEN. 2019;32:16‑28. doi:10.1016/j.clnesp.2019.03.015.

33. Vajdi M, Abbasalizad Farhangi M. Alpha‑lipoic acid supplementation significantly reduces the risk of obesity in an updated systematic review and dose response meta‑analysis of randomised placebo‑controlled clinical trials. Int J Clin Pract. 2020;74(6):e13493. doi:10.1111/ijcp.13493.

34. Mousavi SM, Shab‑Bidar S, Kord‑Varkaneh H, Khorshidi M, Djafarian K. Effect of alpha‑lipoic acid supplementation on lipid profile: a systematic review and meta‑analysis of controlled clinical trials. Nutrition. 2019;59:121‑130. doi:10.1016/j.nut.2018.08.004.

35. Akbari M, Ostadmohammadi V, Lankarani KB, et al. The effects of alpha‑lipoic acid supplementation on glucose control and lipid profiles among patients with metabolic diseases: a systematic review and meta‑analysis of randomized controlled trials. Metabolism. 2018;87:56‑69. doi:10.1016/j.metabol.2018.07.002.

36. Fernández‑Galilea M, Pérez‑Matute P, Prieto‑Hontoria PL, et al. α‑Lipoic acid treatment increases mitochondrial biogenesis and promotes beige adipose features in subcutaneous adipocytes from overweight/obese subjects. Biochim Biophys Acta. 2015;1851(3):273‑281. doi:10.1016/j.bbalip.2014.12.013.

37. Kim H, Kim HJ, Lee K, et al. α‑Lipoic acid attenuates vascular calcification via reversal of mitochondrial function and restoration of Gas6/Axl/Akt survival pathway. J Cell Mol Med. 2012;16(2):273‑286. doi:10.1111/j.1582‑4934.2011.01294.x.

38. Knottnerus SJG, Bleeker JC, Wüst RCI, et al. Disorders of mitochondrial long‑chain fatty acid oxidation and the carnitine shuttle. Rev Endocr Metab Disord. 2018;19(1):93‑106. doi:10.1007/s11154‑018‑9448‑1.

39. Adeva‑Andany MM, Calvo‑Castro I, Fernández‑Fernández C, Donapetry‑García C, Pedre‑Piñeiro AM. Significance of L‑carnitine for human health. IUBMB Life. 2017;69(8):578‑594. doi:10.1002/iub.1646.

40. Reuter SE, Evans AM. Carnitine and acylcarnitines: pharmacokinetic, pharmacological and clinical aspects. Clin Pharmacokinet. 2012;51(9):553‑572. doi:10.1007/BF03261931.

41. Geier DA, Geier MR. L‑carnitine exposure and mitochondrial function in human neuronal cells. Neurochem Res. 2013;38(11):2336‑2341. doi:10.1007/s11064‑013‑1144‑7.

42. Seifert JG, Brumet A, St Cyr JA. The influence of D‑ribose ingestion and fitness level on performance and recovery. J Int Soc Sports Nutr. 2017;14:47. doi:10.1186/s12970‑017‑0205‑8.

43. Derosa G, Pasqualotto S, Catena G, D’Angelo A, Maggi A, Maffioli P. A randomized, double‑blind, placebo‑controlled study to evaluate the effectiveness of a food supplement containing creatine and D‑ribose combined with a physical exercise program in increasing stress tolerance in patients with ischemic heart disease. Nutrients. 2019;11(12):3075. doi:10.3390/nu11123075.

44. Bayram M, St Cyr JA, Abraham WT. D‑ribose aids heart failure patients with preserved ejection fraction and diastolic dysfunction: a pilot study. Ther Adv Cardiovasc Dis. 2015;9(3):56‑65. doi:10.1177/1753944715572752.

45. Stovell MG, Mada MO, Helmy A, et al. The effect of succinate on brain NADH/NAD+ redox state and high energy phosphate metabolism in acute traumatic brain injury. Sci Rep. 2018;8(1):11140. doi:10.1038/s41598‑018‑29255‑3.

46. Giorgi‑Coll S, Amaral AI, Hutchinson PJA, Kotter MR, Carpenter KLH. Succinate supplementation improves metabolic performance of mixed glial cell cultures with mitochondrial dysfunction. Sci Rep. 2017;7(1):1003. doi:10.1038/s41598‑017‑01149‑w.

47. Jalloh I, Helmy A, Howe DJ, et al. Focally perfused succinate potentiates brain metabolism in head injury patients. J Cereb Blood Flow Metab. 2017;37(7):2626‑2638. doi:10.1177/0271678X16672665.

48. Zhang X, Jiang R, Lin H, Xu S. Feeding tricarboxylic acid cycle intermediates improves lactate consumption and antibody production in Chinese hamster ovary cell cultures. Biotechnol Prog. 2020;36(4):e2975. doi:10.1002/btpr.2975.

49. Edwards CB, Copes N, Brito AG, Canfield J, Bradshaw PC. Malate and fumarate extend lifespan in Caenorhabditis elegans. PLoS One. 2013;8(3):e58345. doi:10.1371/journal.pone.0058345.

50. Tardy AL, Pouteau E, Marquez D, Yilmaz C, Scholey A. Vitamins and minerals for energy, fatigue and cognition: a narrative review of the biochemical and clinical evidence. Nutrients. 2020;12(1):228. doi:10.3390/nu12010228.

51. Brunetti D, Dusi S, Giordano C, et al. Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase‑associated neurodegeneration mouse model. Brain. 2014;137(pt 1):57‑68. doi:10.1093/brain/awt325.

52. Tóth F, Cseh EK, Vécsei L. Natural molecules and neuroprotection: kynurenic acid, pantethine and α‑lipoic acid. Int J Mol Sci. 2021;22(1):403. doi:10.3390/ijms22010403.

53. Lejri I, Agapouda A, Grimm A, Eckert A. Mitochondria‑ and oxidative stress‑targeting substances in cognitive decline‑related disorders: from molecular mechanisms to clinical evidence. Oxid Med Cell Longev. 2019;2019:9695412. doi:10.1155/2019/9695412.

54. de Oliveira MR, Nabavi SF, Manayi A, Daglia M, Hajheydari Z, Nabavi SM. Resveratrol and the mitochondria: From triggering the intrinsic apoptotic pathway to inducing mitochondrial biogenesis, a mechanistic view. Biochim Biophys Acta. 2016;1860(4):727‑745. doi:10.1016/j.bbagen.2016.01.017

55. Xia N, Daiber A, Förstermann U, Li H. Antioxidant effects of resveratrol in the cardiovascular system. Br J Pharmacol. 2017;174(12):1633‑1646. doi:10.1111/bph.13492.

56. Bagheri H, Ghasemi F, Barreto GE, Rafiee R, Sathyapalan T, Sahebkar A. Effects of curcumin on mitochondria in neurodegenerative diseases. Biofactors. 2020;46(1):5‑20. doi:10.1002/biof.1566.

57. Trujillo J, Granados‑Castro LF, Zazueta C, Andérica‑Romero AC, Chirino YI, Pedraza‑Chaverrí J. Mitochondria as a target in the therapeutic properties of curcumin. Arch Pharm (Weinheim). 2014;347(12):873‑884. doi:10.1002/ardp.201400266.

58. de Oliveira MR, Jardim FR, Setzer WN, Nabavi SM, Nabavi SF. Curcumin, mitochondrial biogenesis, and mitophagy: Exploring recent data and indicating future needs. Biotechnol Adv. 2016;34(5):813‑826. doi:10.1016/j.biotechadv.2016.04.004.


© 2026 Heilsubarinn ehf. Allur réttur áskilinn.